Pramlintide acetate

American Journal of Health-System Pharmacy

Volumn 62, Issue 22, 2005, Pages 2363-2372

  McQueen, Joanna ^a   Bonk, Mary Ellen ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b University HealthSystem Consortium   (United States)

Author keywords

Antidiabetic agents; Blood levels; Diabetes mellitus; Dosage; Drug administration; Economics; Excretion; Half life; Mechanism of action; Pharmacokinetics; Pramlintide acetate; Toxicity

Indexed keywords

AMYLIN; FRUCTOSAMINE; HEMOGLOBIN A1C; PANCREAS HORMONE; PLACEBO; PRAMLINTIDE;

ANOREXIA; CHRONIC DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; INSULIN RESPONSE; NAUSEA; PATIENT MONITORING; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOCIOECONOMICS; TREATMENT INDICATION; VOMITING;

EID: 28244438412     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050341     Document Type: Review

References (31)

1. Weyer C, Maggs DG, Young AA et al. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Design. 2001; 7: 1353-73.
2. Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes. 2002; 20:137-44.
3. Nyholm B, Ørskov L, Hove K et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism. 1999; 48:935-41.
4. Symlin (pramlintide acetate) injection package insert. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2005.
5. Kleppinger EL, Vivian EM. Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother. 2003; 37:1082-9.
6. Amylin Pharmaceuticals, Inc. Symlin injection (pramlintide acetate) (NDA no. 21-332) advisory committee briefing document. www.fda.gov/ohrms/dockets/ac/ 01/briefing/3761b1_01_Amylin.pdf (accessed 2005 Feb 7).
7. Kruger DF, Gloster MA. Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs. 2004; 64:1419-32.
8. Food and Drug Administration. FDA approves new drug to treat type 1 and type 2 diabetes. Talk paper T05-08. www. fda.gov/bbs/topics/ANSWERS/2005/ ANS01345.html (accessed 2005 Mar 21).
9. Fineman M, Weyer C, Maggs DG et al. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002; 34:504-8.
10. Kong MF, King P, Macdonald IA et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia. 1997; 40:82-8.
11. Kong MF, Stubbs TA, King P et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998; 41:577-83.
12. Thompson RG, Peterson J, Gottlieb A et al. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM; results of a multicenter trial. Diabetes. 1997; 46:632-6.
13. Fineman M, Maggs D, Burrell T et al. Addition of pramlintide to insulin therapy in type 1 diabetes: impact on glycemic and weight control stratified by BMI. Diabetes. 2001; 50(suppl 2):A112. Abstract.
14. Hollander PA, Levy P, Fineman MS et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003; 26:784-90.
15. Ratner RE, Want LL, Fineman MS et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002; 4(1):51-61.
16. Ratner RE, Dickey R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004; 21:1204-12.
17. Thompson RG, Pearson L, Schoenfeld SL et al., and the Pramlintide in Type 2 Diabetes Group. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. Diabetes Care. 1998; 21:987-93.
18. Whitehouse F, Kruger DF, Fineman M et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002; 25:724-30.
19. Hollander P, Maggs DG, Ruggles JA et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004; 12:661-8.
20. Levetan C, Want LL, Weyer C et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care. 2003; 26:1-8.
21. Fineman M, Bahner A, Gottlieb A et al. Effects of six months' administration of pramlintide as an adjunct to insulin therapy on metabolic control in people with type 1 diabetes. Diabetes. 1999; 48(suppl 1):A113-4. Abstract.
22. Gottlieb A, Fineman A, Bahner A et al., for the Pramlintide Type 2 Study Group. Pramlintide therapy in addition to insulin in type 2 diabetes: effect on metabolic control after 6 months. Diabetologia. 1999; 42(suppl 1):A232. Abstract.
23. Thompson RG, Pearson L, Kolterman OG. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia. 1997; 40:1278-85.
24. 1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003; 5:408-14.
25. Maggs DG, Burrell TA, Fineman MS et al. Pramlintide as adjunctive treatment to insulin in type 2 diabetes resulted in improved glycemic control and concomitant weight loss. Diabetes. 2001; 50(suppl 2):A124-5. Abstract.
26. Roman D. Medical officer review: pramlintide acetate (HFD-510). www.fda.gov/ohrms/dockets/ac/01/briefing/3761b1_03_Medical %20Review% 20Safety.pdf (accessed 2005 Apr 5).
27. DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med. 1991; 90:450-9.
28. Weyer C, Fineman MS, Strobel S et al. Properties of pramlintide and insulin upon mixing. Am J Health-Syst Pharm. 2005; 62:816-22.
29. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003; 26:917-32.
30. Red Book Update. 2005; 24(9):50.
31. Amylin agrees to Symlin marketing restrictions in gaining FDA approval. FDC Rep. 2005; Mar 21:12-3.